Short Seller Culper Attacks Tarsus Pharmaceuticals Over XDEMVY Market Size
Culper Research argues Tarsus is significantly overvalued, disputing the addressable market for its Demodex blepharitis drug XDEMVY.
/ 2 items
Culper Research argues Tarsus is significantly overvalued, disputing the addressable market for its Demodex blepharitis drug XDEMVY.
Mizuho initiates coverage on Tarsus Pharmaceuticals with an Outperform rating and a $100 price target, citing strong prospects for Xdemvy and projected peak sales above $2B.